Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, demonstrating high sensitivity for both malignant and advanced precancerous lesions ...

FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted ...

Liquid biopsies have transformed cancer testing. These tests detect signs of cancer using a simple blood draw instead of removing tissue from the body. Traditional biopsies involve surgery, needles, ...

A new blood-based test for colorectal cancer currently up for FDA review could mean cheaper and less invasive screenings for the disease. Doctors and advocates have been waiting for years for a new ...

For years, a diagnosis of colon cancer meant potential surgery followed by a painful round of chemotherapy to kill the remaining cancer cells. One-size-fits-all treatment was normal. A new blood test ...

The ctDNA test showed 79.2% sensitivity and 91.5% specificity for CRC detection in a diverse cohort. The study met primary end points but had limited sensitivity for advanced precancerous lesions.

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to new study in JAMA Oncology.

Colon cancer is the second-deadliest cancer in the US, partly due to low screening rates. New and emerging screening tools, like blood and breath tests, may offer alternatives to in-office screenings.